Franch-Sarto M, Garcia-Calduch O, Rivas A, et al. - Researchers conducted this retrospective multicentre study to analyze the incidence, characteristics, risk factors and outcomes of the central nervous system (CNS) relapses of diffuse large B-cell lymphoma (DLBCL) patients treated with R-CHOP in the Spanish GELTAMO group hospitals. Clinical and biological data, risk factors for CNS relapses, as well as the type of CNS prophylaxis and outcomes of CNS relapses, were collected. In total, 1,530 DLBCL patients from 16 hospitals were involved between 1999 and 2016, a median age of 63 years (range 18-91), 50% males. The frequency and type of CNS relapse were comparable to those previously described (more often in the first year, isolated in CNS and with parenchymal involvement). The only risk factor associated with CNS relapse in this series was CNS-IPI. Overall survival after a CNS relapse was poor, with patients receiving high-dose methotrexate having improved outcomes.